Gilead Science (GILD) Followers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers

GILD 122.59

+1.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Metcalf who wrote (277)	4/28/1997 10:10:00 PM
From: phbolton	of 961

John: some of the stuff they presented last week included direct viral counts for the low viral load individuals. You can only get those nice 5 long reductions on patients over 100,000 counts and the studies have to include patients with a wide range of viral loads. They indicated that there were two individuals, at least, that went from 10**6 to 0. Anyway, the point is the same as you are making: the new therapies are (1) going to make CMV less of a problem and (2) the competition for Gild is going to be tougher than expected, at least by me, in the HIV area.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next